EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis suppurativa and variou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• Cyltezo (adalimumab)

Snippet

Status: Withdrawn. Therapeutic area: Hidradenitis Suppurativa;Arthritis, Psoriatic;Psoriasis;Crohn Disease;Arthritis, Juvenile Rheumatoid;Uveitis;Arthritis, Rheumatoid;Colitis, Ulcerative;Spondylitis, Ankylosing. MAH: Boehringer Ingelheim International GmbH. Decision date: 15/01/2019